



**BPH GLOBAL LTD**  
**ACN 009 104 330**

5 November 2025

Company Announcements Platform  
Australian Securities Exchange

## **Exclusive Dealing Agreement to Evaluate Ginseng-Based Formulation for Male Vitality and Performance**

### **Highlights**

- BPH Global Ltd (ASX: BP8) has entered into a Exclusive Dealing Agreement with Denmark-based scientist Jo-an Refugio, developer of a proprietary ginseng-based formulation.
- The Agreement grants BP8 a six-month exclusive period to conduct due diligence and product testing, including formulation evaluation and laboratory analysis.
- During the exclusivity period, the parties will negotiate commercial terms for BPH Global's potential acquisition of intellectual property rights in the formulation.
- The Company may also consider engaging Jo-an as an R&D consultant in relation to further product development.
- The formulation aligns with the Company's new R&D focus on Traditional Chinese Medicine (TCM)-based natural formulations targeting male vitality and wellbeing.

### **Exclusive Dealing and Confidentiality Agreement with Jo-an Refugio**

The Board of BPH Global Ltd (**ASX: BP8**) (**BPH Global** or **Company**) advises that it has executed a Confidentiality and Exclusivity Agreement with Denmark-based scientist Jo-an Refugio (**Agreement**) to facilitate the evaluation and potential acquisition of a proprietary ginseng-based formulation developed by Jo-an.

Under the Agreement, BPH Global has secured a six-month exclusivity period commencing 5 November 2025. During this period, the Company will conduct technical and laboratory testing of the formulation, including impurity and stability assessments, to evaluate its suitability for commercialisation.

The exclusivity arrangement also provides a framework for the parties to negotiate terms for a commercial agreement, under which BPH Global may acquire intellectual property rights to the formulation and consider engaging Jo-an as an R&D consultant to assist in further development and optimisation of the product.

As consideration for the exclusivity, a non-refundable exclusivity fee of AUD 9,000 is payable to Jo-an.

### **About the Ginseng-Based Formulation**

The proprietary formulation, developed in accordance with Traditional Chinese Medicine (TCM) principles, includes Panax ginseng as a key ingredient together with other complementary herbal components. The product is designed to support male vitality and overall wellbeing through natural mechanisms associated with healthy circulation and energy balance.

The formulation forms part of the Company's broader R&D initiative exploring two development pathways:

- **Natural Over-the-Counter (OTC) Products:** Formulations containing natural ingredients such as ginseng, positioned as wellness and vitality products without therapeutic claims.
- **Evidence-Based Products:** Formulations that, following successful preliminary evaluation, may be advanced into evidence-based, clinically tested products supported by scientific validation.

### **Next Steps**

During the six-month exclusivity period, the Company will conduct due diligence testing on the ginseng-based formulation and evaluate commercial terms for a definitive agreement with Jo-an.

Further updates will be provided as material developments occur.

This announcement has been authorised by the Board of Directors.

- END -

For further information, please visit our website at <https://bphglobal.com> or contact the Company Secretary on 03 9088 2049.